Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.
A study by Vanderbilt researchers sheds light on how current antidepressant drugs work and suggests a new drug target in depression.
Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Preventing the formation of secretory structures that promote scarring in the kidney could offer new therapeutic options for a disease that affects millions of people worldwide.
Accessibility Tools